Inga Hansen-Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P Nicolay, Jana D Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D Braun, Marion Wobser, Claus-Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai-Christian Klespe, Stefan W Schneider, Nina Booken
{"title":"治疗皮肤T细胞淋巴瘤的聚乙二醇干扰素α2a--对70名患者的多中心回顾性数据分析。","authors":"Inga Hansen-Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P Nicolay, Jana D Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D Braun, Marion Wobser, Claus-Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai-Christian Klespe, Stefan W Schneider, Nina Booken","doi":"10.1111/ddg.15511","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL.</p><p><strong>Patients and methods: </strong>A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers.</p><p><strong>Results: </strong>In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently.</p><p><strong>Conclusions: </strong>Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.</p>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.\",\"authors\":\"Inga Hansen-Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P Nicolay, Jana D Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D Braun, Marion Wobser, Claus-Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai-Christian Klespe, Stefan W Schneider, Nina Booken\",\"doi\":\"10.1111/ddg.15511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL.</p><p><strong>Patients and methods: </strong>A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers.</p><p><strong>Results: </strong>In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently.</p><p><strong>Conclusions: </strong>Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.</p>\",\"PeriodicalId\":14758,\"journal\":{\"name\":\"Journal Der Deutschen Dermatologischen Gesellschaft\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal Der Deutschen Dermatologischen Gesellschaft\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ddg.15511\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Der Deutschen Dermatologischen Gesellschaft","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ddg.15511","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.
Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL.
Patients and methods: A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers.
Results: In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently.
Conclusions: Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.
期刊介绍：
The JDDG publishes scientific papers from a wide range of disciplines, such as dermatovenereology, allergology, phlebology, dermatosurgery, dermatooncology, and dermatohistopathology. Also in JDDG: information on medical training, continuing education, a calendar of events, book reviews and society announcements.
Papers can be submitted in German or English language. In the print version, all articles are published in German. In the online version, all key articles are published in English.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
